H. R. 8857
Introduced in House · June 2, 2026May 15, 2026
Mr. Morelle (for himself, Mr. Gottheimer, Mr. Pfluger, and Mr. Kean) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned
A BILL
To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. Short title.
This Act may be cited as the “Next Generation Medicines Act of 2026” or the “Next GEN Act of 2026”.